Paper #754

Título:

Patentes, regulación de precios e innovación en la industria farmacéutica

Autor:

Vicente Ortún

Data:

Mayo 2004

Resumen:

The trade-off between property rights/price regulation and innovation depends on country characteristics and drug industry specificities. Access to drugs and innovation can be reconciled by seven ways that, among others, include: public health strengthening in the countries with the largest access problems (those among the poor with the weakest institutions); public and private aid to make attractive R&D on neglected diseases; price discrimination with market segmentation; to require patent owners to choose either protection in the rich countries or protection in the poor countries (but not both). Regarding price regulation, after a review of theoretical arguments and empirical evidence, seven strategies to reconcile health and industrial considerations are outlined, including: mitigation of the medical profession dependence on the pharmaceutical industry; consideration of a drug as an input of a production process; split drug authorization from public funding decisions; establish an efficiency minimum for all health production inputs; and stop the European R&D hemorrhagia.

Palabras clave:

I+D farmacéutico, acceso a medicamentos, patentes, regulación de precios, política industrial, política sanitaria

Códigos JEL:

I18, D45, P35, K23

Área de investigación:

Economía Laboral, Pública, de Desarrollo y de la Salud

Númuero serie CRES:

38

Publicado en:

Cuadernos económicos de ICE 2004, 67, pp. 191-207

Descargar el paper en formato PDF